Lipid trafficking and the control of postprandial hypertriglyceridemia. For Moxisylyte (hydrochloride) biological activity instance, CD36 is expressed all through the intestinal tract and is important for the metabolism and the secretion of chylomicron into the lymph. The molecule is required for efficient intestinal absorption of LCFA and VLCFA. Yet, CD36 deficient mice exhibit a normal level of FA absorption and gene 848354-66-5 deletion does not affect LCFA uptake and TG re-esterification in mouse jejunum. Therefore the potential of CD36 as a therapeutic target is debated. In the present paper we have identified small chemical molecules which have the capacity to inhibit the FA and ox-LDL receptor function of CD36. These inhibitors were able to rescue well characterized animal models from postprandial hypertriglyceridemia and atherosclerosis with a concomitant improvement of insulin resistance and glucose tolerance. The CD36-inhibitor activity of this new chemical series was established on the following criteria. First, the molecules were Second, consistent with the dual function of CD36 as a receptor for two different ligands, and the non-competitive agonist activity of these inhibitors, a similar activity on LCFA binding and uptake on both THP1 and HEK-CD36 cells was measured. These results support a receptor rather than a ligand-driven inhibition. Third, analogs of the same series with close chemical structure had no effect on these cellular functions, suggesting the existence of a structure-function relationship within the members of the series. Finally, cross-linking affinity was used to demonstrate the effect of the compounds on the molecular interaction between ox-LDL and CD36. In aggregate, these new molecules were able to inhibit the CD36 receptor function both at the cellular and the molecular levels. The first CD36 in vivo activity to be examined was its implication in the development of atherosclerosis using a well characterized animal model. A DKO mouse combining LDL-R and leptin deficiencies was used. This model exhibits high blood pressure together with increased plasma TG concentration, insulin and glucose. It develops atherosclerosis and represents a good model to study the physiopathology of the metabolic syndrome. The CD36-antagonists used in the present study were able to reduce the growth of
